Quadruple test nhsmail
The Quadruple Test!
The Quadruple Test, also known as the Triple Screen Test, is a prenatal screening test used to detect certain birth defects and chromosomal abnormalities in a developing fetus. It's typically performed between 15 and 20 weeks of pregnancy.
Here's what the test checks for:
- Alpha-fetoprotein (AFP): This protein is produced by the fetus and can indicate neural tube defects (NTDs) such as spina bifida or anencephaly.
- Human chorionic gonadotropin (hCG): This hormone is produced by the placenta and can indicate Down syndrome (trisomy 21) and other chromosomal abnormalities.
- Unconjugated estriol (uE3): This hormone is produced by the placenta and can indicate Down syndrome and other chromosomal abnormalities.
- Inhibin-A: This hormone is produced by the placenta and can indicate Down syndrome and other chromosomal abnormalities.
The test results are usually reported as a risk score, which indicates the likelihood of the fetus having a specific condition. A high risk score doesn't necessarily mean the fetus has a condition, but it may indicate the need for further testing, such as chorionic villus sampling (CVS) or amniocentesis.
The Quadruple Test is not a diagnostic test, but rather a screening test. It's important to note that while it can detect certain conditions, it's not 100% accurate and may not detect all cases of a particular condition.
If you're considering the Quadruple Test, be sure to discuss the risks and benefits with your healthcare provider, and ask about any additional testing or screening options that may be available to you.